Precision Biosciences (DTIL) Interest Expenses (2018 - 2026)
Precision Biosciences' (DTIL) quarterly Interest Expenses came in at $499000.0 in Q1 2026, up 3.1% year-on-year from $484000.0 in Q1 2025, and down 43.81% on a QoQ basis from $888000.0 in Q4 2025.
Precision Biosciences (DTIL) Interest Expenses (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Interest Expenses data on file, last reported at $499000.0 in Q1 2026.
- On a quarterly basis, Interest Expenses rose 3.1% year-over-year to $499000.0 in Q1 2026; TTM through Mar 2026 was $2.4 million, a 3.22% increase from a year earlier, with the FY2025 full-year figure at $145.3 million, up 6.14% from the prior year.
- Interest Expenses for Q1 2026 stood at $499000.0, down from $888000.0 in the prior quarter.
- Over the last five years, Interest Expenses for DTIL reached as high as $10.4 million in Q2 2024 and fell as low as $297000.0 in Q3 2023.
- Historically, Interest Expenses has averaged $3.3 million across 5 years, with a median of $888000.0 in 2025.
- Across the five-year window, Interest Expenses sank 95.02% in 2022 and surged 3250.84% in 2024, its largest moves.
- Year by year, Interest Expenses stood at $1.8 million in 2022, then slumped by 59.88% to $739000.0 in 2023, then slumped by 32.61% to $498000.0 in 2024, then surged by 78.31% to $888000.0 in 2025, then plunged by 43.81% to $499000.0 in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $499000.0 in Q1 2026, $888000.0 in Q4 2025, and $8.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Precision Biosciences | 184.64 Mn | 156.34 Mn | - | 499,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 499,000.00 |
| Mar 31, 2026 | 499,000.00 |
| Dec 31, 2025 | 888,000.00 |
| Dec 31, 2025 | 888,000.00 |
| Sep 30, 2025 | 8.01 Mn |
| Sep 30, 2025 | 8.01 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 484,000.00 |
| Mar 31, 2025 | 484,000.00 |
| Dec 31, 2024 | 498,000.00 |
| Dec 31, 2024 | 498,000.00 |
| Sep 30, 2024 | 9.95 Mn |
| Sep 30, 2024 | 9.95 Mn |
| Jun 30, 2024 | 10.42 Mn |
| Jun 30, 2024 | 10.42 Mn |
| Mar 31, 2024 | 574,000.00 |
| Mar 31, 2024 | 574,000.00 |
| Dec 31, 2023 | 739,000.00 |
| Dec 31, 2023 | 739,000.00 |